{"id":2246,"date":"2026-06-27T19:41:19","date_gmt":"2026-06-27T19:41:19","guid":{"rendered":"https:\/\/one-peptides.com\/?post_type=product&p=2246"},"modified":"2026-10-05T13:49:43","modified_gmt":"2026-10-05T13:49:43","slug":"oxytocin-spray-10mg","status":"publish","type":"product","link":"https:\/\/one-peptides.com\/es\/producto\/oxytocin-spray-10mg\/","title":{"rendered":"Oxytocin Spray 10 mg"},"content":{"rendered":"

One-Peptides OXYTOCIN 10 mg \u2014 OXTR nonapeptide nasal spray for laboratory research<\/h2>\n

OXYTOCIN 10 mg nasal spray is a research reagent (Research Use Only)<\/strong> supplied as a pre-dissolved solution. This product is a synthetic nonapeptide intended solely for laboratory research into oxytocin receptor (OXTR) signalling and social neurobiology. It is not a medicine, a dietary supplement or a product for human use.<\/strong> Although oxytocin as an injectable substance (Syntocinon, Oxytocin) is an authorised obstetric medicine, this RUO reagent in spray form belongs to a separate regulatory framework<\/strong> \u2014 it is not a medicinal product and does not replace any medicine. The entire description concerns receptor pharmacology and findings reported in the literature; it does not and cannot contain any claims of “bonding”, “treating anxiety, depression or autism” or any other health effect in humans.<\/strong><\/em><\/p>\n

Oxytocin is one of the earliest characterised and most widely studied peptides in the history of neuroendocrinology \u2014 and, at the same time, one of those around which the greatest number of oversimplifications has accumulated. In 1953 Vincent du Vigneaud synthesised it as the first peptide hormone obtained chemically, which two years later earned him the Nobel Prize. For decades it was associated almost exclusively with two classic physiological functions \u2014 uterine contractions during labour and the stimulation of lactation. It was only from the 1990s onwards that research teams began systematically describing another side of this peptide: its role in the brain as a neuromodulator of social behaviour, social cognition and the regulation of the stress response.<\/p>\n

In the One Peptides catalogue, oxytocin is supplied as a chemical reagent for research use only (RUO)<\/strong> in the format of a pre-dissolved nasal spray. The choice of this form is not incidental: intranasal administration is one of the most intensively explored directions in human oxytocin research, described in the context of the nose\u2013brain axis. The solution does not require reconstitution of a lyophilisate<\/a>, and the dosing system allows for the reproducible withdrawal of the peptide under controlled conditions. This is a technical solution for teams working on OXTR signalling and social neurobiology in research models \u2014 not a form intended for administration to humans.<\/p>\n

Oxytocin<\/strong> is a natural nonapeptide<\/strong> (nine amino acids) with a cyclic structure closed by a disulphide bridge, and an agonist of the oxytocin receptor (OXTR). It is produced in neurons of the hypothalamus and released by the posterior lobe of the pituitary gland. In neurobiology it is studied as a modulator of social behaviour, bonding, social cognition and the stress response. In laboratory circulation it is available solely as a research reagent (RUO).<\/em><\/p>\n

What oxytocin is \u2014 sequence and class<\/h2>\n

Oxytocin<\/a> is one of the smallest biologically active regulatory peptides in the body. Its amino acid sequence reads Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH\u2082<\/strong>, and its characteristic structural feature is a disulphide bridge<\/strong> linking the cysteine residues at positions 1 and 6. This bridge closes a six-amino-acid ring, from which a three-amino-acid “tail” (Pro-Leu-Gly-NH\u2082) protrudes, terminating in an amide group. It is precisely this compact, rigidified structure that determines how the peptide binds to its receptor.<\/p>\n

The target receptor is OXTR<\/strong> \u2014 the oxytocin receptor belonging to the family of G protein-coupled receptors (GPCRs). It occurs both in peripheral tissues (uterus, mammary gland) and in numerous structures of the central nervous system, including areas involved in processing social and emotional stimuli. Structurally, oxytocin is very close to vasopressin (they differ by only two amino acids at positions 3 and 8), which translates into a degree of mutual cross-activity of both peptides towards their receptors \u2014 an important detail when interpreting the results of receptor studies.<\/p>\n

Naturally, oxytocin is synthesised in neurons of the paraventricular nucleus (PVN)<\/strong> and the supraoptic nucleus (SON)<\/strong> of the hypothalamus, from where it is transported axonally to the posterior lobe of the pituitary gland and released into circulation in response to stimuli. In addition to this classic neurohormonal route, direct oxytocinergic projections from the PVN to brain structures have also been identified \u2014 these form the anatomical basis for interest in oxytocin as a central neuromodulator.<\/p>\n

Chemical characteristics<\/h3>\n\n\n\n\n\n\n\n\n\n\n\n\n
Parameter<\/th>\nValue<\/th>\n<\/tr>\n<\/thead>\n
Class<\/td>\nNonapeptide (9 amino acids), oxytocin receptor (OXTR) agonist<\/td>\n<\/tr>\n
Sequence<\/td>\nCys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH\u2082 (cyclic, disulphide bridge Cys\u00b9\u2013Cys\u2076)<\/td>\n<\/tr>\n
Molecular mass<\/td>\n~1007 Da<\/td>\n<\/tr>\n
Target receptor<\/td>\nOXTR \u2014 a G protein-coupled receptor (GPCR)<\/td>\n<\/tr>\n
Physical form<\/td>\nPre-dissolved solution, nasal spray (no reconstitution)<\/td>\n<\/tr>\n
Content<\/td>\n10 mg oxytocin<\/td>\n<\/tr>\n
HPLC purity<\/td>\n\u226598%<\/td>\n<\/tr>\n
Identity confirmation<\/td>\nMass spectrometry (MS)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Mechanism of action in research<\/h2>\n

Oxytocin exerts its action through agonism of the OXTR receptor<\/strong>. Binding of the peptide to the G protein-coupled receptor triggers an intracellular signalling cascade \u2014 depending on the cell type, primarily the Gq protein\/phospholipase C pathway, leading to the mobilisation of intracellular calcium. In peripheral tissues this translates into classic physiological effects (contraction of smooth muscle), whereas in the central nervous system OXTR signalling is studied in an entirely different context \u2014 as a modulator of the activity of neuronal circuits involved in processing social stimuli.<\/p>\n

In the neurobiological literature, oxytocin is described as a neuromodulator of social behaviour<\/strong>. Research on OXTR signalling focuses on several areas: social cognition (the recognition and processing of social signals), the response to stimuli related to bonding, and the regulation of the stress response. In animal models, the role of oxytocin in the formation of pair bonds in monogamous species has been analysed, among other things, as well as its influence on the activity of limbic structures, including the amygdala \u2014 a structure central to the processing of emotion and the fear response.<\/p>\n

An important interpretative caveat: the central mechanism of oxytocin is complex and context-dependent<\/strong>. Contemporary literature has moved away from the simple narrative of “the more oxytocin, the more trust” towards a picture in which the effects of OXTR signalling depend on the social context, the baseline state of the organism and the specific neuronal circuit. The reference data come from in vitro receptor studies, animal models and controlled studies involving humans conducted at academic centres \u2014 and describe how the system works, not any application beyond the laboratory.<\/p>\n

Nasal spray format \u2014 research context<\/h2>\n

Here the format has a genuine scientific rationale. Of all neuroactive peptides, intranasal oxytocin is one of the most intensively studied directions in humans<\/strong> \u2014 there is an extensive body of literature analysing the influence of intranasal administration on social cognition, the processing of emotional stimuli and the stress response under controlled conditions. The reason for interest in this route is the concept of the nose\u2013brain axis<\/strong>: the richly vascularised and innervated nasal mucosa, adjacent to the olfactory pathways and the trigeminal nerve, is sometimes considered a potential route for transporting molecules to the central nervous system with limited involvement of the general circulation.<\/p>\n

The nasal spray format<\/a> makes the same reagent available as a pre-dissolved solution intended for research into intranasal administration<\/strong>. The solution does not require reconstitution \u2014 it is ready for laboratory work in accordance with the experimental plan, and the dosing system ensures reproducibility of withdrawal.<\/p>\n

Full honesty about the scientific status of this route is, however, necessary. Despite the large number of publications, the mechanism and reproducibility of the effects of intranasal oxytocin remain the subject of active debate and replication<\/strong>. Some studies have not confirmed earlier observations, and questions about how much of the peptide actually reaches brain structures after intranasal administration still have no unambiguous answer. The format should therefore be treated as a tool for research into this route of administration, rather than as a pathway with an established, confirmed profile in humans.<\/p>\n

Oxytocin RUO vs oxytocin as a medicine<\/h2>\n

The same molecule operates within two entirely separate regulatory frameworks, which must not be confused. The comparison below sets out the difference.<\/p>\n\n\n\n\n\n\n\n\n\n\n
Aspect<\/th>\nOxytocin RUO (this product)<\/th>\nOxytocin as a medicine<\/th>\n<\/tr>\n<\/thead>\n
Status<\/td>\nResearch reagent (Research Use Only)<\/td>\nAuthorised medicinal product<\/td>\n<\/tr>\n
Example names<\/td>\n\u2014 (chemical reagent)<\/td>\nSyntocinon, Oxytocin<\/td>\n<\/tr>\n
Form<\/td>\nPre-dissolved solution, nasal spray<\/td>\nSolution for injection \/ infusion (injection)<\/td>\n<\/tr>\n
Context<\/td>\nResearch into OXTR signalling and social neurobiology<\/td>\nObstetrics \u2014 induction and augmentation of labour, support of lactation<\/td>\n<\/tr>\n
Intended use<\/td>\nLaboratory use only, not for humans<\/td>\nUse in humans under medical supervision<\/td>\n<\/tr>\n
Authorisation<\/td>\nNo authorisation as a medicine or supplement<\/td>\nEMA \/ FDA authorisation as a medicine<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The conclusion is unambiguous: the fact that oxytocin exists as an authorised injectable medicine in obstetrics does not make the RUO reagent in spray form a medicine.<\/strong> This product is not a medicinal product, has no obstetric application and cannot be regarded as a substitute for any medical preparation. It is a laboratory tool \u2014 and remains solely that.<\/p>\n

Applications in scientific research<\/h2>\n

Oxytocin is one of the few neuropeptides to have been the subject of a broad research programme<\/a> \u2014 from the receptor level to controlled trials involving humans at academic centres. The overview below is purely scientific in nature: it describes what has been studied, and does not suggest any application beyond the laboratory.<\/p>\n

OXTR receptor pharmacology.<\/strong> The fundamental direction is the characterisation of oxytocin binding to the OXTR receptor and the signalling cascade triggered following activation. In vitro receptor studies analyse affinity, selectivity relative to related vasopressin receptors and the dynamics of the cellular response \u2014 this is the foundation for interpreting all observations at higher levels of organisation.<\/p>\n

Models of social behaviour.<\/strong> In animal models, oxytocin is a tool for studying the neurobiology of bonding and prosocial behaviour. Classic experiments in monogamous species (prairie voles) demonstrated the involvement of oxytocin signalling in the formation of pair bonds, opening up an entire field of research into the neuronal basis of social behaviour.<\/p>\n

Stress neurobiology and social cognition.<\/strong> A separate area is the role of oxytocin in regulating the stress response and in processing social stimuli. Brain imaging studies (fMRI) in humans have analysed the modulation of the activity of limbic structures, including the amygdala, in response to social and emotional stimuli \u2014 as research into the mechanism of action of the system, rather than confirmation of any therapeutic effect.<\/p>\n

The interpretative framework remains unambiguous: these are studies of physiology and mechanism, conducted under controlled conditions, often in small groups, assessing the acute response of the system to administration of the peptide. They are not authorisation studies nor material justifying use beyond the laboratory.<\/p>\n

One Peptides quality specification<\/h2>\n

Every batch of oxytocin nasal spray undergoes a full process of analytical control.<\/p>\n